PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
申请人:AMGEN INC.
公开号:US20150252011A1
公开(公告)日:2015-09-10
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:
wherein variables A
4
, A
5
, A
6
, A
8
, each of R
a
, R
b
, R
1
, R
2
, R
3
and R
7
of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.
本发明提供了一类新的化合物,可用于调节β-分泌酶(BACE)的活性。这些化合物具有通式I:
其中,变量A4、A5、A6、A8,以及通式I中的每个Ra、Rb、R1、R2、R3和R7,在此独立地定义。本发明还提供了包含这些化合物的药物组合物,并将这些化合物和组合物用于治疗与A-beta斑块形成和沉积有关的疾病和/或症状,这是由BACE的生物活性导致的。这样的BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。本发明还提供了通式II和III的化合物,以及它们的亚式化合物、中间体和制备本发明化合物的方法。